Page 35 - GTM-4-2

Global Translational Medicine Small RNA therapy for pancreatic cancer

doi: 10.18632/oncotarget.22634 Xenobiotica. 2015;45(7):642-652.
27. Ellenrieder V, Alber B, Lacher U, et al. Role of MT-MMPs doi: 10.3109/00498254.2014.1001809
and MMP-2 in pancreatic cancer progression. Int J Cancer. 38. Adamska A, Elaskalani O, Emmanouilidi A, et al. Molecular
2000;85(1):14-20.
and cellular mechanisms of chemoresistance in pancreatic
doi: 10.1002/(sici)1097-0215(20000101)85:1<14:aid- cancer. Adv Biol Regul. 2018;68:77-87.
ijc3>3.0.co;2-o
doi: 10.1016/j.jbior.2017.11.007
28. Hui B, Ji H, Xu Y, et al. RREB1-induced upregulation of 39. Gu A, Li J, Qiu S, et al. Pancreatic cancer environment: From
the lncRNA AGAP2-AS1 regulates the proliferation and patient-derived models to single-cell omics. Mol Omics.
migration of pancreatic cancer partly through suppressing 2024;20(4):220-233.
ANKRD1 and ANGPTL4. Cell Death Dis. 2019;10(3):207.
doi: 10.1039/d3mo00250k
doi: 10.1038/s41419-019-1384-9
40. Zhang Y, Xu M. Research advances in the mechanism of
29. Silke J, O’Reilly LA. NF-κB and pancreatic cancer; Chapter tumor microenvironment in pancreatic cancer and related
and verse. Cancers (Basel). 2021;13(18):4510.
targeted therapy. J Clin Hepatol. 2022;38(4):965-968.
doi: 10.3390/cancers13184510
doi: 10.3969/j.issn.1001-5256.2022.04.046
30. Du Z, Zhang Q, Xiang X, et al. RRM2 promotes liver metastasis 41. Cencioni C, Malatesta S, Vigiano Benedetti V, et al.
of pancreatic cancer by stabilizing YBX1 and activating the The GLP-1R agonist semaglutide reshapes pancreatic
TGF-beta pathway. iScience. 2024;27(10):110864.
cancer associated fibroblasts reducing collagen proline
doi: 10.1016/j.isci.2024.110864 hydroxylation and favoring T lymphocyte infiltration. J Exp
Clin Cancer Res. 2025;44(1):18.
31. Li R, Liu R, Xu Y, et al. Suppressing pancreatic cancer survival
and immune escape via nanoparticle-modulated STING/ doi: 10.1186/s13046-024-03263-w
STAT3 axis regulation. Bioconjug Chem. 2024;35(11): 42. Li Y, VandenBoom TG 2 , Kong D, et al. Up-regulation
nd
1815-1822.
of miR-200 and let-7 by natural agents leads to the
doi: 10.1021/acs.bioconjchem.4c00379 reversal of epithelial-to-mesenchymal transition in
gemcitabine-resistant pancreatic cancer cells. Cancer Res.
32. Martinez S, Wu S, Geuenich M, et al. In vivo CRISPR screens
reveal SCAF1 and USP15 as drivers of pancreatic cancer. 2009;69(16):6704-6712.
Nat Commun. 2024;15(1):5266. doi: 10.1158/0008-5472.Can-09-1298
doi: 10.1038/s41467-024-49450-3 43. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits
human pancreatic cancer tumor-initiating cells. PLoS One.
33. Gu A, Li J, Li MY, Liu Y. Patient-derived xenograft model in
cancer: Establishment and applications. MedComm (2020). 2009;4(8):e6816.
2025;6(2):e70059. doi: 10.1371/journal.pone.0006816
doi: 10.1002/mco2.70059 44. Kent OA, Fox-Talbot K, Halushka MK. RREB1
repressed miR-143/145 modulates KRAS signaling
34. Raffenne J, Nicolle R, Puleo F, et al. hENT1 testing in
pancreatic ductal adenocarcinoma: Are we ready? A through downregulation of multiple targets. Oncogene.
multimodal evaluation of hENT1 status. Cancers (Basel). 2013;32(20):2576-2585.
2019;11(11):1808. doi: 10.1038/onc.2012.266
doi: 10.3390/cancers11111808 45. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear
factor kappaB in pancreatic cancer metastasis. Clin Cancer
35. Elander NO, Aughton K, Ghaneh P, et al. Expression of
dihydropyrimidine dehydrogenase (DPD) and hENT1 Res. 2003;9(1):346-354.
nd
predicts survival in pancreatic cancer. Br J Cancer. 46. Li Y, Vandenboom TG 2 , Wang Z, et al. miR-146a
2018;118(7):947-954. suppresses invasion of pancreatic cancer cells. Cancer Res.
2010;70(4):1486-1495.
doi: 10.1038/s41416-018-0004-2
doi: 10.1158/0008-5472.Can-09-2792
36. Arana MR, Altenberg GA. ATP-binding cassette exporters:
Structure and mechanism with a focus on P-glycoprotein 47. Yan H, Wu J, Liu W, et al. MicroRNA-20a overexpression
and MRP1. Curr Med Chem. 2019;26(7):1062-1078. inhibited proliferation and metastasis of pancreatic
carcinoma cells. Human Gene Ther. 2010;21(12):1723-1734.
doi: 10.2174/0929867324666171012105143
doi: 10.1089/hum.2010.061
37. Kohan HG, Boroujerdi M. Time and concentration
dependency of P-gp, MRP1 and MRP5 induction in response 48. Zhao G, Zhang JG, Shi Y, et al. MiR-130b is a prognostic
to gemcitabine uptake in Capan-2 pancreatic cancer cells. marker and inhibits cell proliferation and invasion in

Volume 4 Issue 2 (2025) 27 doi: 10.36922/gtm.8247